Additional file 1 of Pulmonary toxicity and translocation of gallium phosphide nanowires to secondary organs following pulmonary exposure in mice

Abstract

Supplementary Material 1: Experimental details and results of the pilot study and 3-months study. GaP NW synthesis and characterization in pilot study. Table S1: Pilot study design. Figure S1: Characterization of GaP NWs in the pilot study. Table S2: (Pilot study) Cellular composition of bronchoalveolar lavage 1 and 3 days after exposure to GaP NWs. Figure S2: (Pilot study) Histopathology of mouse lung 1 and 28 days after pulmonary exposure to GaP NWs. Table S3: 3-month study design. Figure S3: Additional darkfield of GaP NWs in tissues. Figure S4: Chemical identification by EDS of GaP NWs in lung tissue 1 day after exposure. Figure S5: SEM images of GaP NWs in lung tissue day 1 and 28 and 3 months post-exposure. Table S4: Diameter of gold nanoparticles and nanowires in vivo and in vitro. Figure S6, Table S5 and S6: Cellular composition of bronchoalveolar lavage 1, 3, 28 days and 3 months after exposure to GaP NWs, carbon black or MWCNT Mitsui-7. Figure S7 and Table S7: Genotoxicity in BAL cells, lung and liver tissue in 3-month study. Table S8. Mouse lung histopathology 1, 28 days and 3 months after intratracheal instillation of GaP NWs, incidence table. Table S9: Composition of phagolysosomal simulant fluid (PSF). Table S10: Composition of low-calcium Gamble’s solution